
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.
Kyverna is seeking a hands-on Process Engineer to support process development for autologous CAR T cell products. The role will focus on developing, optimizing, and transferring upstream and downstream processes to GMP. Process development will focus on closing and automating product formulation and fill/finish steps, and integration with robotics systems. This individual designs experiments supporting these ends and creates objectives to support the company’s goals. The role requires strong partnership with functions within technical operations including Analytical Development, Quality, and Manufacturing, and with other internal and external stakeholders. The ideal candidate will leverage their experience in cell therapy process development and partner cross-functionally with MSAT, manufacturing, analytical development, and quality to enable robust, GMP-ready processes.
Department: Technical Development
Location: Emeryville, CA (On-site)
Reports To: Sr. Director, Process Development
The salary range for this position is from $135,000. To $150,000. USD annually. This salary range is an estimate of what we reasonably expect to pay for this posted position, and the actual salary may vary based on various factors, including without limitation individual education, experience, tenure, skills and abilities, as well as internal equity and alignment with market data. This position is also eligible for bonus, benefits, and participation in Company’s stock plan.

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.